AU2021280623B9 - Interleukin 29 mutant protein - Google Patents

Interleukin 29 mutant protein Download PDF

Info

Publication number
AU2021280623B9
AU2021280623B9 AU2021280623A AU2021280623A AU2021280623B9 AU 2021280623 B9 AU2021280623 B9 AU 2021280623B9 AU 2021280623 A AU2021280623 A AU 2021280623A AU 2021280623 A AU2021280623 A AU 2021280623A AU 2021280623 B9 AU2021280623 B9 AU 2021280623B9
Authority
AU
Australia
Prior art keywords
protein
seq
mutant
amino acid
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021280623A
Other languages
English (en)
Other versions
AU2021280623A1 (en
AU2021280623B2 (en
Inventor
Jing Feng
Wanjun GUO
Yan Li
Hai Pan
Liu Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciwind Biosciences Co Ltd
Original Assignee
Sciwind Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciwind Biosciences Co Ltd filed Critical Sciwind Biosciences Co Ltd
Publication of AU2021280623A1 publication Critical patent/AU2021280623A1/en
Application granted granted Critical
Publication of AU2021280623B2 publication Critical patent/AU2021280623B2/en
Publication of AU2021280623B9 publication Critical patent/AU2021280623B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2021280623A 2020-05-27 2021-02-08 Interleukin 29 mutant protein Active AU2021280623B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020092613 2020-05-27
CNPCT/CN2020/092613 2020-05-27
PCT/CN2021/075907 WO2021238302A1 (zh) 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白

Publications (3)

Publication Number Publication Date
AU2021280623A1 AU2021280623A1 (en) 2023-02-02
AU2021280623B2 AU2021280623B2 (en) 2024-02-29
AU2021280623B9 true AU2021280623B9 (en) 2024-03-14

Family

ID=78745522

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021280623A Active AU2021280623B9 (en) 2020-05-27 2021-02-08 Interleukin 29 mutant protein

Country Status (6)

Country Link
US (1) US12703728B2 (enExample)
EP (1) EP4159748A4 (enExample)
JP (1) JP7741108B2 (enExample)
CN (1) CN115667291B (enExample)
AU (1) AU2021280623B9 (enExample)
WO (1) WO2021238302A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140086A2 (en) * 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Serum albumin binding molecules
WO2015103749A1 (en) * 2014-01-08 2015-07-16 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
CN105085658A (zh) * 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031316A (zh) 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
US7351689B2 (en) 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
JP2009502803A (ja) 2005-07-20 2009-01-29 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法
CN103224951A (zh) 2013-01-25 2013-07-31 江南大学 人白细胞介素29成熟肽第35位精氨酸定点突变为赖氨酸的变异体及其制备方法
CN103224952A (zh) 2013-01-25 2013-07-31 江南大学 人白细胞介素29成熟肽第33位赖氨酸、35位精氨酸定点突变为精氨酸、赖氨酸的变异体及其制备方法
CN103923209B (zh) 2014-05-13 2016-06-22 北京凯因科技股份有限公司 一种Lambda干扰素突变体及聚乙二醇衍生物
CN105085657A (zh) 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种干扰素突变体及聚乙二醇衍生物
CN104402988A (zh) 2014-12-12 2015-03-11 江南大学 一种人白细胞介素-29的重组变异体及其制备方法
CN112694526B (zh) * 2020-05-27 2023-01-20 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140086A2 (en) * 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Serum albumin binding molecules
WO2015103749A1 (en) * 2014-01-08 2015-07-16 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
CN105085658A (zh) * 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物

Also Published As

Publication number Publication date
JP2023527048A (ja) 2023-06-26
EP4159748A4 (en) 2024-02-21
AU2021280623A1 (en) 2023-02-02
CN115667291B (zh) 2025-08-05
EP4159748A1 (en) 2023-04-05
US20230265144A1 (en) 2023-08-24
WO2021238302A1 (zh) 2021-12-02
US12703728B2 (en) 2026-08-11
CN115667291A (zh) 2023-01-31
JP7741108B2 (ja) 2025-09-17
AU2021280623B2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
CN111315878B (zh) 经修饰l-天冬酰胺酶
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
EP4282880A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
AU2020401160A1 (en) Pharmaceutical TACI-Fc fusion protein formulation
CN101255197A (zh) 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
AU2021280623B2 (en) Interleukin 29 mutant protein
CN112870336B (zh) 一种白细胞介素29突变体蛋白制剂
CN112694526B (zh) 一种白细胞介素29突变体蛋白
WO2021164576A1 (zh) 用于抗冠状病毒感染的药物及其应用
CN111961135A (zh) 一种用于预防或治疗癌症的抗体
CN119119196A (zh) 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用
WO2020108427A1 (zh) 一种新型干扰素α及其制备方法、组合物和用途
CN115385998B (zh) 稳定的iii型干扰素蛋白及其融合蛋白
CN114949180A (zh) 治疗肺炎支原体感染的药物的筛选方法与波形蛋白的应用
CN118684738A (zh) 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂
WO2024192698A1 (zh) 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂
CN111825773B (zh) 重组人TSG6-IFNα融合蛋白及其制备方法以及其作为抗病毒药物的应用
US20230374091A1 (en) Annexin a5 compositions and methods
WO2010043046A1 (en) Peptide inhibitors of type iii secretion
CN1403588B (zh) Hiv-1蛋白酶elisa检测方法及用于多靶位筛选hiv-1抑制剂
CN111333699A (zh) 一种多肽或其衍生物及其在制备防治肿瘤的药物中的应用
HK40083738A (en) Soluble ace2 and fusion protein, and applications thereof
WO2023208199A1 (zh) 调控HIF-3α的活性分子在治疗疾病中的应用
CN120098150A (zh) 一种广谱抗新型冠状病毒的双靶点多肽及其应用
CN117003859A (zh) 抗新型冠状病毒人源化纳米抗体及其应用

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)